Robert Ghenchev Overview
- Firm
- Novo Holdings
- Primary Position
-
Managing Partner...
- Primary Industry
-
Healthcare
- Active Board Seats
-
2
- Med. Deal Size
-
- Med. Valuation
-
Robert Ghenchev General Information
Biography
Mr. Robert Ghenchev serves as Managing Partner and Head of Growth Investments & Member of the Life Sciences Operating Committee at Novo Holdings. He serves as Vice President at Moelis & Company. He joined Novo Holdings in January 2018 as a director of the Principal Investments team, responsible for growth equity investments. Before joining Novo Holdings, he was a Senior Vice President at Moelis & Company in London where he focused on mergers and acquisitions within the Healthcare Industry. Before Moelis, he was part of the UK Mergers & Acquisitions team at Deutsche Bank in London. He holds a J.Hons. B.A. degree in Finance and Economics from McGill University and an M.Sc. degree in Financial Economics from the University of Oxford. He also serves as a Board Member at Tempus, Quanta Dialysis Technologies, and Exscientia. He served as a Board Member at Mission Bio.
Contact Information
Address
- One Market Street, Steuart Tower
- 17th Floor
- San Francisco, CA 94105
- United States
Robert Ghenchev Positions (1)
Firm name | Firm type | Title | Location | Industry | Since |
---|---|---|---|---|---|
Novo Holdings | Investor | Managing Partner and Head of Growth Investments & Member of the Life Sciences Operating Committee | Copenhagen, Denmark | Corporate Venture Capital |
Robert Ghenchev Board Seats (2)
Company | Industry | Ownership Status | Financing Status | Location | Since |
---|---|---|---|---|---|
Oxford BioMedica | Biotechnology | Publicly Held | Corporation | Oxford, United Kingdom | |
Quanta Dialysis Technologies | Other Devices and Supplies | Privately Held (backing) | Venture Capital-Backed | Warwick, United Kingdom |
Robert Ghenchev Lead Partner on Deals (11)
Robert Ghenchev has been the lead partner on 11 deals. Their latest deal was with Quanta Dialysis Technologies, a other devices and supplies company. The deal was made for on 18-Nov-2024.
Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
---|---|---|---|---|---|---|
Quanta Dialysis Technologies | 18-Nov-2024 | Later Stage VC (Series E) | Completed | Other Devices and Supplies | Warwick, United Kingdom | |
Mission Bio | 06-May-2022 | Completed | Discovery Tools (Healthcare) | San Francisco, CA | ||
Quanta Dialysis Technologies | 23-Jun-2021 | Completed | Other Devices and Supplies | Warwick, United Kingdom | ||
Exscientia | 27-Apr-2021 | Completed | Drug Discovery | Oxford, United Kingdom | ||
Tempus AI | 10-Dec-2020 | Completed | Biotechnology | Chicago, IL | ||
Mission Bio | 13-Aug-2020 | Completed | Discovery Tools (Healthcare) | San Francisco, CA | ||
Oxford BioMedica | 23-Jun-2020 | Completed | Biotechnology | Oxford, United Kingdom | ||
Tempus AI | 13-Mar-2020 | Completed | Biotechnology | Chicago, IL | ||
Tempus AI | 30-May-2019 | Later Stage VC (Series F) | Completed | Biotechnology | Chicago, IL | |
Oxford BioMedica | 28-May-2019 | PIPE | Completed | Biotechnology | Oxford, United Kingdom |
Robert Ghenchev Network (220)
Board Members (71)
Name | Company | Representing | Location | From |
---|---|---|---|---|
William Hyun Ph.D | Mission Bio | Genoa Ventures | San Francisco, CA | |
Lloyd Mandell | Quanta Dialysis Technologies | Glenview Capital Management | Warwick, United Kingdom | |
Quanta Dialysis Technologies | Self | Warwick, United Kingdom | ||
Quanta Dialysis Technologies | Self | Warwick, United Kingdom | ||
Mission Bio | Mayfield Fund | San Francisco, CA |
Portfolio Executives (118)
Name | Company | Role | Deal date | Location |
---|---|---|---|---|
Alejandro Galindo | Quanta Dialysis Technologies | Chief Executive Officer | 18-Nov-2024 | Warwick, United Kingdom |
Willem Baralt | Quanta Dialysis Technologies | Chief Financial Officer | 18-Nov-2024 | Warwick, United Kingdom |
Quanta Dialysis Technologies | Chief Engineer | 18-Nov-2024 | Warwick, United Kingdom | |
Quanta Dialysis Technologies | Chief Medical Officer | 18-Nov-2024 | Warwick, United Kingdom | |
Quanta Dialysis Technologies | Co-Founder, Chief Executive Officer & Board Member | 18-Nov-2024 | Warwick, United Kingdom |
Fund Team Members (31)
Name | Investor | Fund | Fund Location |
---|---|---|---|
Aleks Engel Ph.D | Novo Holdings | Repair Impact Fund | Copenhagen, Denmark |
Aleks Engel Ph.D | REPAIR Impact Fund | Repair Impact Fund | Hellerup, Denmark |
Novo Holdings | Copenhagen, Denmark | ||
REPAIR Impact Fund | Hellerup, Denmark | ||
Novo Holdings | Copenhagen, Denmark |
Robert Ghenchev Affiliated Funds (2)
Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
---|---|---|---|---|---|---|---|---|
Repair Impact Fund | Novo Holdings | Venture Capital - Early Stage | Closed | 2018 | ||||
Renewable Energy Partnership I | Novo Holdings | Infrastructure Debt | Closed | 2021 |
Robert Ghenchev FAQs
-
Who is Robert Ghenchev?
Mr. Robert Ghenchev serves as Managing Partner and Head of Growth Investments & Member of the Life Sciences Operating Committee at Novo Holdings.
-
How much does Robert Ghenchev typically invest?
Robert Ghenchev's median deal size is
. -
What is Robert Ghenchev’s main position?
Robert Ghenchev’s primary position is Managing Partner and Head of Growth Investments & Member of the Life Sciences Operating Committee.
-
How many active board seats does Robert Ghenchev hold?
Robert Ghenchev holds 2 board seats including Oxford BioMedica and Quanta Dialysis Technologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »